CancerVMRTPNCT01854541
Visual Management for the Radiotherapy Process
An observational study of Cancer, run by Maastricht Radiation Oncology at 1 site in Netherlands.
Trial summary
The Visual Management for Radiotherapy Practice (VMRTP) aims to analyze, predict, visualize and shorten the waiting times for radiotherapy patients. The hypothesis is that this can be done by the introduction of models that can predict a patient being at risk for waiting too long as well as visual management tools… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cancer
- How many people
- 10,000 participants
- Where
- 1 siteNetherlands
- Study dates
- Mar 2013to Jan 2015
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients treated with radiotherapy
Who may be able to join
- Patients receiving radiotherapy
Who cannot join
- Patients not receiving radiotherapy
Trial locations and contacts
1 site in 1 country.
About this study
The Visual Management for Radiotherapy Practice (VMRTP) aims to analyze, predict, visualize and shorten the waiting times for radiotherapy patients. The hypothesis is that this can be done by the introduction of models that can predict a patient being at risk for waiting too long as well as visual management tools that visualize the radiotherapy process.
Read the detailed description
In a retrospective cohort of radiotherapy patients, time stamps of various steps in the radiotherapy process (diagnosis, multi-disciplinary board, referral, intake, simulation, treatment planning, quality control, first fraction of radiotherapy) will be collected. These will be combined with patient, tumor and patient-process (e.g. referring physician, treating physician, busy-at-the-time, referring hospital) related features. Based on these a predictive model will be learned that can estimate the probability at various stages of the process that the patient waits too long. Visual management will be developed that can visualize the predicted waiting time.
Process interventions aimed at reducing waiting times will be tested prospectively.
- Conditions
- Cancer
- Keywords
- Cancer, Radiotherapy
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Radiotherapy | All patients receiving radiotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
referral and first day of radiotherapy
Waiting time between referral and first day of radiotherapy
Measured: 3 months
Secondary outcomes (4)
Diagnosis and first day of radiotherapy
Waiting time between diagnosis and first day of radiotherapy
Measured: 3 months
multi-disciplinary board and first day of radiotherapy
Waiting time between multi-disciplinary board and first day of radiotherapy
Measured: 3 months
intake and first day of radiotherapy
Waiting time between intake and first day of radiotherapy
Measured: 3 months
simulation and first day of radiotherapy
Waiting time between simulation and first day of radiotherapy
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2013 (estimated)
- Study startMar 2013
- Primary completionJan 2015
- Study completionJan 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Enrolment
- 10,000 participants (actual)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Maastricht Radiation Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- Maastro Clinic, The Netherlands
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01854541
- Sponsor's protocol ID
- VMRTP
- Acronym
- VMRTP
- Status last verified
- Apr 2015
- First submitted
- 13 May 2013
- Last updated
- 10 Apr 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Visual Management for the Radiotherapy Process
- ClinicalTrials.gov ID
- NCT01854541
- Acronym / sponsor ID
- VMRTP / VMRTP
- Conditions
- Cancer
- Keywords
- Cancer, Radiotherapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 10,000 participants (actual)
- Lead sponsor
- Maastricht Radiation OncologyUniversity, hospital or other
- Collaborators
- Maastro Clinic, The Netherlands
- Study start
- Mar 2013
- Primary completion
- Jan 2015 (actual)
- Study completion
- Jan 2015 (actual)
- First posted
- 15 May 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Visual Management for Radiotherapy Practice (VMRTP) aims to analyze, predict, visualize and shorten the waiting times for radiotherapy patients. The hypothesis is that this can be done by the introduction of models that can predict a patient being at risk for waiting too long as well as visual management tools that visualize the radiotherapy process.
Detailed description
In a retrospective cohort of radiotherapy patients, time stamps of various steps in the radiotherapy process (diagnosis, multi-disciplinary board, referral, intake, simulation, treatment planning, quality control, first fraction of radiotherapy) will be collected. These will be combined with patient, tumor and patient-process (e.g. referring physician, treating physician, busy-at-the-time, referring hospital) related features. Based on these a predictive model will be learned that can estimate the probability at various stages of the process that the patient waits too long. Visual management will be developed that can visualize the predicted waiting time.
Process interventions aimed at reducing waiting times will be tested prospectively.
Study design
- Observational model
- Cohort
- Target follow-up
- 3 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Radiotherapy | – | –All patients receiving radiotherapy |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients treated with radiotherapy
Key inclusion criteria (1 listed)
- Patients receiving radiotherapy
Key exclusion criteria (1 listed)
- Patients not receiving radiotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
referral and first day of radiotherapy
Time frame: 3 months
Waiting time between referral and first day of radiotherapy
4 secondary outcomes
Diagnosis and first day of radiotherapy
Time frame: 3 months
multi-disciplinary board and first day of radiotherapy
Time frame: 3 months
intake and first day of radiotherapy
Time frame: 3 months
simulation and first day of radiotherapy
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2015.
Related trials for Cancer
RecruitingPhase 1
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
Solid Tumor
RecruitingPhase 1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Maastricht Radiation Oncology at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
referral and first day of radiotherapy (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2015.